Want to see INTS full AI Analyst Report?
Top Page
Intensity Therapeutics, Inc.
(NASDAQ:INTS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.50
▲(1.12% Upside)
Action:Reiterated
Date:07/08/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and continued cash burn), partially offset by a low-debt balance sheet. Technicals are mixed (near-term strength vs. longer-term downtrend), while valuation is limited by a negative P/E and no dividend data; corporate events were modestly positive but include potential dilution from expanded equity plans.
Positive Factors
Low financial leverage and rebuilt capitalization
A very low debt load and improved equity base provide structural financial flexibility for a pre-revenue biotech. Lower leverage reduces interest burden and preserves optionality to fund clinical programs via equity or partnerships without heavy fixed-cost constraints.
Negative Factors
Pre-revenue with persistent net losses
Being pre-revenue with recurring sizable net losses means the company lacks internally generated income to fund operations. Over the medium term this necessitates external capital or partnering to sustain development and creates ongoing execution and dilution risk for shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage and rebuilt capitalization
A very low debt load and improved equity base provide structural financial flexibility for a pre-revenue biotech. Lower leverage reduces interest burden and preserves optionality to fund clinical programs via equity or partnerships without heavy fixed-cost constraints.
Read all positive factors
Intensity Therapeutics, Inc. (INTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.03M
Dividend YieldN/A
Average Volume (3M)51.49K
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue GrowthN/A
EPS Growth73.15%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.97
Shares Outstanding2,702,820
10 Day Avg. Volume22,859
30 Day Avg. Volume51,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)11.72
Price to Sales (P/S)0.00
P/FCF Ratio-15.07
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit458.87
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$30.00Price Target Upside574.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.46
Revenue Forecast (FY)N/A
Intensity Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, ...
How the Company Makes Money
null...
Intensity Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | -26.00K | 0.00 | -147.00K | 0.00 | 0.00 |
| EBITDA | -7.95M | -11.61M | -16.27M | -10.09M | -7.32M | -7.88M |
| Net Income | -10.69M | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
Balance Sheet | ||||||
| Total Assets | 12.29M | 14.10M | 4.78M | 17.30M | 1.76M | 5.22M |
| Cash, Cash Equivalents and Short-Term Investments | 10.24M | 11.92M | 2.59M | 14.78M | 1.31M | 4.54M |
| Total Debt | 102.00K | 110.00K | 138.00K | 158.00K | 4.49M | 2.34M |
| Total Liabilities | 2.31M | 2.23M | 1.86M | 4.13M | 16.86M | 13.90M |
| Stockholders Equity | 9.98M | 11.88M | 2.92M | 13.16M | -15.10M | -8.68M |
Cash Flow | ||||||
| Free Cash Flow | -9.07M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Operating Cash Flow | -9.07M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Investing Cash Flow | 0.00 | 0.00 | 6.35M | -6.02M | 0.00 | 0.00 |
| Financing Cash Flow | 18.39M | 18.56M | 2.90M | 20.47M | 2.25M | 2.05M |
Intensity Therapeutics, Inc. Technical Analysis
Negative
4.45
Price Trends
4.33
Positive
5.10
Negative
7.44
Negative
Market Momentum
0.06
Positive
48.13
Neutral
9.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 4.45 is below the 20-day moving average (MA) of 4.58, above the 50-day MA of 4.33, and below the 200-day MA of 7.44, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 48.13 is Neutral, neither overbought nor oversold. The STOCH value of 9.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.
Intensity Therapeutics, Inc. Risk Analysis
Intensity Therapeutics, Inc. disclosed 62 risk factors in its most recent earnings report. Intensity Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intensity Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $12.03M | -0.64 | -136.82% | ― | ― | 73.15% | |
42 Neutral | $745.20K | >-0.01 | -55.81% | ― | ― | 88.07% | |
42 Neutral | $910.75K | ― | -29.84% | ― | -1.80% | -198.00% | |
| ― | $2.31M | -0.08 | -177.32% | ― | ― | 84.00% |
* Healthcare Sector Average
INTS
Intensity Therapeutics, Inc.
4.57
-3.46
-43.05%
BDRX
Biodexa Pharmaceuticals
1.57
-41.43
-96.35%
QCLS
Q/C Technologies
3.22
-12.22
-79.15%
SCNI
Scinai Immunotherapeutics
0.25
-1.75
-87.70%
OGEN
Oragenics
0.50
-0.86
-63.16%
Intensity Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting
Positive
Jun 16, 2026
On June 16, 2026, Intensity Therapeutics, Inc. held its annual meeting of stockholders via live webcast, with about 40.74% of eligible common shares represented, constituting a quorum. Stockholders elected two Class III directors, Dr. Emer Leahy a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.